Q3 saw a return to EBITDA profitability and nearly 50% revenue growth, led by strong BD partnership performance. The Zimmer Biomet contract termination impacts long-term targets, but the trauma segment partnership continues and wound management showed robust growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.